Dr. Wagstaff on the Survival Benefit of Immunotherapy in Bladder Cancer
John Wagstaff, MD, professor at Swansea University Medical School, discusses the survival benefit of immunotherapy for patients with bladder cancer.
Most of the trials have been conducted with single-agent checkpoint inhibitors, explains Wagstaff. These trials showed response rates in the second-line setting of 15% to 25%.
Patients with melanoma who respond to immunotherapy see years of survival benefit; however, longer follow-up is needed to determine if this is the case in bladder cancer, states Wagstaff.